Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences is conducting a clinical study titled ‘A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer.’ The study aims to evaluate the safety, tolerability, and effectiveness of sacituzumab govitecan-hziy (SG) in treating advanced triple-negative breast cancer (TNBC). This research is significant as it explores alternative dosing schedules to potentially improve patient outcomes.
The intervention being tested is sacituzumab govitecan-hziy (SG), an intravenous drug designed to target and treat TNBC by potentially enhancing the objective response rate and progression-free survival.
The study employs a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. It is structured in two phases: Phase 1 assesses preliminary safety and efficacy, while Phase 2 expands on these findings.
The study began on April 30, 2025, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 8, 2025, indicating ongoing recruitment and progress.
This study update could influence Gilead Sciences’ stock performance positively, as successful outcomes may enhance their market position in oncology. Investors should also consider the competitive landscape, where advancements in TNBC treatment are highly sought after.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.